
Claims

1. Compound of the general formula (I) as defined hereinafter:



Formula (I),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein:

R_1 is a 5-6 membered heteroaryl containing 0-1 oxygen, 0-1 sulfur and/or 0-4 nitrogen, optionally substituted with 1-5 substituents R1a,

R1a is independently selected and represent hydrogen, deuterium, halogen, (C1-C3) alkyl, (C3-C5) cycloalkyl, -C(=O)-CH3, partially or fully halogenated (C1-C3) alkyl, (C1-C3) alkylsulfonyl, cyano, N,N-dimethylamine, N-methylamine, -C(=O)-NH-(C1-C5)-alkyl;

R2, R3, R4, R5 are each independently selected and are:

(i) hydrogen, deuterium, halogen, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, -C(=O)-CH3, partially or fully halogenated (C1-C3)alkyl, or

(ii) -OH, -SH, or

(iii) -(C1-C3)-alkoxy, 3-7-membered heterocyclyl containing 0-2 nitrogen atoms, 0-1 oxygen atom and/or 0-1 sulfur atom, (C3-C7)-cycloalkyl, -S-(C1-C3)-alkyl, -(C3-C7)-cycloalkyl-S- (C1-C3)-alkyl, wherein each of the above groups is optionally partially or completely substituted with substituents selected from -OH, deuterium, 1-4 halogen atoms, (C1-C3)-alkoxy, (C3-C7)-cycloalkyl, oxo group, -(C1-C3)-alkyl-(C3-C6)-cycloalkyl, (C1-C5)-alkyl, partially or fully halogenated (C1-C5) alkyl, (C2-C3) alkenyl, (C2-C3) alkynyl, (C1-C3) alkoxy, -NH2, 3-7-membered heterocycle containing one oxygen atom, (C1-C3)-alkylamino, di(C1-C3)- alkylamino or 3-7-membered heterocycle containing one nitrogen atom and optionally 1-2 oxygen and/or sulfur heteroatoms; or

(iv) 4-7-membered heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen atom and/or 0-1 sulfur atom, necessarily substituted with 1-4 substituents selected from oxo group or - (C1-C3)-alkyl-(C3-C6)-cycloalkyl, and also optionally substituted with 1-3 substituents selected from deuterium, halogen, (C1-C5)-alkyl, partially or fully halogenated (C1-C5) alkyl, (C2-C3) alkenyl, (C2-C3) alkynyl and (C1-C3) alkoxy, or

(v) -NRaRb, where each Ra and Rb:

is independently hydrogen, deuterium, (C3-C7)-cycloalkyl, -(C1-C3)-alkyl-N(CH3)2, (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, 3-7 membered heterocyclyl containing 0-1 oxygen atom, 0-1 sulfur atom and/or 0-4 nitrogen atoms, optionally substituted with 1-2 substituents selected from (C1- C3)-alkyl or partially or fully halogenated (C1-C3)-alkyl, 5-7-membered heteroaryl containing 0-1 oxygen atom, 0-1 sulfur atom and/or 0-4 nitrogen atoms, said heteroaryl being optionally substituted with 1-2 substituents selected from deuterium, halogen, (C1-C3)-alkyl or partially or fully halogenated (C1-C3)-alkyl,

alternatively, Ra and Rb together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen atom and/or 0-1 sulfur atom, optionally substituted with 1-4 substituents selected from (C1-C5)-alkyl, partially or fully halogenated (C1-C5)-alkyl, oxo group, -(C1-C3)-alkyl-(C3-C6)-cycloalkyl, (C2-C3)-alkenyl, (C2-C3)-alkynyl, (C1-C3) alkoxy or

alternatively, Ra and Rb together with the nitrogen atom to which they are attached form a 6-14-membered bicyclic heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen and/or 0-1 sulfur atoms, optionally substituted with 1-4 substituents selected from deuterium, halogen, (C1-C5)-alkyl, partially or fully halogenated (C1-C5)-alkyl, (C2-C3)-alkenyl, (C2-C3) alkynyl, oxo group or -(C1-C3)-alkyl-(C3-C6)-cycloalkyl or (C1-C3) alkoxy;

wherein at least two of R2, R3, R4, R5 is other than hydrogen;

D/S - means the presence of a double or single bond;

dashed bonds mean the rings are aromatic.

2. A compound according to claim 1, wherein at least three of R2, R3, R4 and R5 are other than hydrogen.

3. A compound according to claim 1, wherein R2, R3, R4 и R5 are each independently selected and represent:

(i) hydrogen, deuterium, halogen, (C1-C3)-alkyl, (C3-C5)-cycloalkyl, -C(=O)-CH3, partially or fully halogenated (C1-C3)-alkyl;

(ii) a group selected from (C1-C3)-alkoxy, (C3-C7)cycloalkyl, halogenated (C1-C3)alkoxy group containing 1-4 halogen atoms;

(iii) -NRaRb, where each Ra and Rb:

is independently hydrogen, deuterium, (C3-C7)-cycloalkyl, -(C1-C3)-alkyl-N(CH3)2, (C1- C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, 3-7 membered heterocyclyl containing 0-1 oxygen atom, 0-1 sulfur atom and/or 0-4 nitrogen atoms, optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, 5-7 membered heteroaryl containing 0-1 oxygen atom, 0-1 sulfur atom and/or 0-4 nitrogen atoms, optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl,

alternatively, Ra and Rb together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen atom and/or 0-1 sulfur atom, optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, or

alternatively, Ra and Rb together with the nitrogen atom to which they are attached form a 6-14-membered bicyclic heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen and/or 0-1 sulfur atom, optionally substituted with 1-4 substituents selected from deuterium, halogen, (C1- C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, (C2-C3)-alkenyl, (C2-C3)-alkynyl or (C1- C3)-alkoxy;

wherein at least two of R2, R3, R4, R5 is other than hydrogen.

4. A compound according to claim 1, wherein at least one of the radicals R2, R3, R4, R5 is in the para position and each is independently selected and represent:

-OH, -SH, (C1-C3)-alkoxy, 3-7-membered heterocyclyl containing 0-2 nitrogen atom, 0-1 oxygen atom and/or 0-1 sulfur atom, (C3-C7)-cycloalkyl, -S-(C1-C3)-alkyl, (C3-C7)-cycloalkylS-(C1-C3)-alkyl, wherein each of the above groups is optionally partially or completely substituted with substituents selected from -OH, 1-4 halogen atoms, (C1-C3)-alkoxy, (C3-C7)-cycloalkyl, 3-7-membered heterocycle containing one oxygen atom, -NH2, (C1-C3)-alkylamino, di(C1-C3)-alkylamino or 3-7-membered heterocycle containing one nitrogen atom and optionally 1-2 oxygen and sulfur heteroatoms; or

NRaRb, where each Ra and Rb:

is independently hydrogen, (C3-C7)-cycloalkyl, -(C1-C3)-alkyl-N(CH3)2, (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, 3-7 membered heterocycle containing 0-1 oxygen atom, 0-1 sulfur and 1-4 nitrogen atoms, optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl or partially or fully halogenated (C1-C3)-alkyl, 5-7 membered heteroaryl containing 1-2 nitrogen atom, wherein said heteroaryl is optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl or partially or fully halogenated (C1-C3)-alkyl,


alternatively, Ra and Rb together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen atom and/or 0-1 sulfur atom, optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, or

alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a 6-14-membered bicyclic heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen and/or 0-1 sulfur atoms, optionally substituted with 1-4 substituents selected from halogen, (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, (C2-C3)-alkenyl, (C2-C3)-alkynyl or (C1-C3) alkoxy.

5. A compound according to claim 1, wherein R_1 is independently selected from pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazyl, wherein R_1 is optionally substituted with group selected from methyl, methylsulfonyl, halogen, methylamino, cyano and cyclopropyl.

6. A compound according to claim 1, wherein two of R2, R3, R4, R5 are in meta position and are a group selected from methyl or halogen, one of R2, R3, R4, R5 is hydrogen and one of R2, R3, R4, R5 is in para position and is a group selected from methoxy, isopropyloxy, cyclopropylmethoxy, difluoroethoxy, -NH2, -N(CH3)2, cyclopropylamino, -N(CH3)-cyclobutyl, N(CH3)-methylthiazolyl, methylpiperidylamino, -NH-(C1-C3)-alkyl-N(CH3)2, morpholinyl, methylpiperazinyl, optionally methyl-substituted azetidinyl, thiomorpholinyl, optionally methyl-substituted hexahydropyrrolopyrrolyl, diazaspirononanyl, optionally substituted with methyl octahydropyrrolopyridinyl.

7. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (Ia):



Formula (Ia),

or a pharmaceutically acceptable salt or solvate or hydrate thereof, wherein:

R1 as defined in claim 1,

R6 is chosen independently and is:

-OH, -SH, -(C1-C3)-alkoxy, 3-7 membered heterocyclyl containing 0-1 oxygen atoms and/or 0-1 sulfur atom, (C3-C7)-cycloalkyl, -S-(C1-C3)-alkyl, (C3-C7)-cycloalkyl-S-(C1-C3)-alkyl, wherein each of the above groups is optionally partially or completely substituted with substituents selected from -OH, 1-4 halogen atoms, (C1-C3)-alkoxy, (C3-C7)-cycloalkyl, 3-7 membered heterocycle containing one oxygen atom, -NH2, (C1-C3)-alkylamino, di(C1-C3)-alkylamino or 3-7-membered heterocycle containing one nitrogen atom and optionally 1-2 heteroatoms selected from oxygen and sulfur, or


-NRaRb, where each Ra and Rb:

is independently hydrogen, (C3-C7)-cycloalkyl, -(C1-C3)-alkyl-N(CH3)2, (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, 3-7 membered heterocycle containing 0-1 oxygen 20 atom, 0-1 sulfur and/or 1-4 nitrogen, optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl or partially or fully halogenated (C1-C3)-alkyl, 5-7 membered heteroaryl containing 0-1 oxygen, 0-1 sulfur and/or 1-4 nitrogen, said heteroaryl being optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl or partially or fully halogenated (C1-C3)-alkyl,

alternatively Ra and Rb together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen atoms and/or 0-1 sulfur atoms, optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, or

alternatively, Ra and Rb, together with the nitrogen atom to which they are attached, form a 6-14-membered bicyclic heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen and/or 0-1 sulfur atoms, optionally substituted with 1-4 substituents selected from halogen, (C1-C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, (C2-C3)-alkenyl, (C2-C3) alkynyl or (C1-C3) alkoxy.

8. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (IIa):




Formula (IIa),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein:

R1 and R6 as defined in claim 7.

9. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (Ib):




Formula (Ib),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein: Q1, Q2, Q3, Q4, Q5 are each independently selected and are nitrogen or carbon, where no more than two of Q1, Q2, Q3, Q4, and Q5 are nitrogen, and said carbon is optionally substituted with 1-5 substituents R1a,

R2, R3, R4, R5 and R1a as defined in claim 1;

dotted bonds mean the rings are aromatic.

10. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (Ic):




Formula (Ic),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein: Q6, Q7, Q8, Q9 are each independently selected and are oxygen, carbon, or nitrogen, with no more than two of Q6, Qz, Qs and Q9 being nitrogen or oxygen, and said carbon is optionally substituted with 1-2 R1a groups,

R2, R3, R4, R5 and R1a as defined in claim 1,

dotted bonds mean the rings are aromatic.

11. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (Id):




Formula (Id),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein:

Q1, Q2, Q3, Q4, Q5 as defined in claim 9;

R6 as defined in claim 7.

12. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (Ie):




Formula (Ie),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein:

Q6, Q7, Q8, Q9 as defined in claim 10;

R6 as defined in claim 7.

13. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (If):




Formula (If),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein:

R1 as defined in claim 1;

R6 as defined in claim 7.

14. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (IIb):



Formula (IIb),


or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein

Q1, Q2, Q3, Q4, Q5 as defined in claim 9;

R2, R3, R4 and R5 as defined in claim 1;

dotted bonds mean the rings are aromatic.

15. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (IId):




Formula (IId),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein:

Q1, Q2, Q3, Q4, Q5 and as defined in claim 9;

R6 as defined in claim 7.

16. A compound according to claim 1, wherein the compound of formula (I) is a compound whose structure is described by Formula (IIId):



Formula (IIId),

or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein:

Q1, Q2, Q3, Q4 are each independently represent nitrogen or carbon;

if R' independently represents hydrogen, deuterium, halogen, (C1-C3) alkyl, (C3-C5) cycloalkyl, -C(=O)-CH3, partially or fully halogenated (C1-C3) alkyl, (C1-C3) alkylsulfonyl, cyano, N,N-dimethylamine, N-methylamine, then R'2 independently represents 4-7-membered heterocyclyl containing 1-2 nitrogen atoms, 0-1 oxygen atom and/or 0-1 sulfur atom, necessary substituted 1-2 substituents selected from oxo group or -(C1-C3)-alkyl-(C3-C6)-cycloalkyl, and also optionally substituted with 1-3 substituents selected from deuterium, halogen, (C1-C5)-alkyl, partially or fully halogenated (C1-C5) alkyl, (C2-C3) alkenyl, (C2-C3) alkynyl and (C1-C3) alkoxy; or

if R'1 independently represents -C(=O)-NH-(C1-C5)-alkyl; then R2 independently represents:

NRcRd, where each Rc and Rd:

is independently hydrogen, deuterium, (C3-C7)-cycloalkyl, -(C1-C3)-alkyl-N(CH3)2, (C1- C3)-alkyl, partially or fully halogenated (C1-C3)-alkyl, 3-7 membered heterocyclyl containing 0-1 oxygen atom, 0-1 sulfur atom and/or 0-4 nitrogen atoms, optionally substituted with 1-2 substituents selected from (C1- C3)-alkyl or partially or fully halogenated (C1-C3)-alkyl, 5-7- membered heteroaryl containing 0-1 oxygen atom, 0-1 sulfur atom and/or 0-4 nitrogen atoms, said heteroaryl being optionally substituted with 1-2 substituents selected from (C1-C3)-alkyl or partially or fully halogenated (C1-C3)-alkyl,

alternatively, Rc and Rd together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen atom and/or 0-1 sulfur atom, optionally substituted with 1-4 substituents selected from deuterium, halogen, (C1- C5)-alkyl, partially or fully halogenated (C1-C5)-alkyl, (C2-C3)-alkenyl, oxo group, -(C1-C3)-alkyl- (C3-C6)-cycloalkyl or (C1-C3) alkoxy, or

alternatively, Rc and Rd together with the nitrogen atom to which they are attached form a 6-14-membered bicyclic heterocyclyl containing 1-2 nitrogen atoms and 0-1 oxygen and/or 0-1 sulfur atoms, optionally substituted with 1-4 substituents selected from deuterium, halogen, (C1- C5)-alkyl, partially or fully halogenated (C1-C5)-alkyl, (C2-C3)-alkenyl, (C2-C3) alkynyl, oxo group, -(C1-C3)-alkyl-(C3-C6)-cycloalkyl or (C1-C3) alkoxy.

17. The compound according to claim 1, selected from the group:

1-(4-methoxy-3,5-dimethylphenyl)sulfonyl-4-(5-methyl-2-pyridyl)pyrrolo[2,3-c]pyridine;

1-((4-Methoxy-3,5-dimethylphenyl)sulfonyl)-4-(5-methylpyrazin-2-yl)-1H-pyrrolo[2,3- c]pyridine;

1-((4-methoxy-3,5-dimethylphenyl)sulfonyl)-4-(5-methylpyrimidin-2-yl)-1H-pyrrolo[2,3- c]pyridine;

1-(4-methoxy-3,5-dimethylphenyl)sulfonyl-4-(6-methylpyridazin-3-yl)pyrrolo[2,3- c]pyridine;

1-(4-methoxy-3,5-dimethylphenyl)sulfonyl-4-(5-methylsulfonyl-2-pyridyl)pyrrolo[2,3- c]pyridine;

1-((3,5-difluoro-4-isopropoxyphenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridine;

1-((4-(cyclopropylmethoxy)-3,5-difluorophenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3- c]pyridine;

1-((4-(2,2-difluoroethoxy)-3,5-difluorophenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3- c]pyridine;

2,6-difluoro-N,N-dimethyl-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)aniline;

4-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)morpholine;

2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)aniline;

1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3- c]pyridine;

2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)aniline;

N-cyclobutyl-2,6-difluoro-N-methyl-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1- yl)sulfonyl)aniline;

2,6-difluoro-N,N-dimethyl-4-((4-(pyridin-2-yl)-2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-1- yl)sulfonyl)aniline;

2,6-difluoro-4-((4-(pyridin-2-yl)-2,3-dehydro-H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenol;

1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-2,3-dihydro1H-pyrrolo[2,3- c]pyridine;

1-((3,5-difluoro-4-methoxyphenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridine;

1-((3,5-difluoro-4-(3-methylazetidin-1-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3- c]pyridine;

N-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)-N,4- dimethylthiazol- 2-amine;

N-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)-1- methylpiperidin-4-amine;

N1-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)-N2,N2- dimethylethane- 1,2-diamine;

4-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)thiomorpholine;

1-((3,5-difluoro-4-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenyl)sulfonyl)-4- (pyridin-2-yl)-1H-pyrrolo [2,3-s]pyridine;

1-((3,5-difluoro-4-(5-methyloctahydro-2H-pyrrolo[3,4-c]pyridin-2-yl)phenyl)sulfonyl)-4- (pyridin-2-yl)-1H- pyrrolo[2,3-c]pyridine;

2-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)-2,7- diazaspiro[4.4]nonane;

2-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)oxazol-4-carbonitrile;

5-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)picolinonitrile;

1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-4-(5-fluoropyrimidin-2-yl)-1Hpyrrolo[2,3-c]pyridine;

5-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)-N-methylpyrazin- 2-amine;

4-(5-cyclopropylpyridin-2-yl)-1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)- 1H-pyrrolo[2,3-c]pyridine;

2,6-difluoro-4-((4-(5-methylpyrazin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)aniline;

2,6-difluoro-N,N-dimethyl-4-((4-(5-methylpyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1- yl)sulfonyl)aniline;

4-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)-1- methylpiperazin-2-one;

1-((4-(4-(cyclopropylmethyl)piperazin-1-yl)-3,5-difluorophenyl)sulfonyl)-4-(pyridin-2-yl)- 1H-pyrrolo[2,3-c]pyridine;

N-(tert-butyl)-5-(1-((3,5-difluoro-4-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)- yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4-yl)picolinamide;

1-((3,5-difluoro-4-(piperazin-1-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3- 10 c]pyridine;

6-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)-N-methylpyridin-3-amine;

5-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)-N-methylpyridin-2-amine;

6-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)-N,N-dimethylpyridin-3-amine;

5-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)pyrazine-2-carbonitrile;

6-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)nicotinonitrile;

6-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)-N-methylpyridazin-3-amine;

2-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)-N-methylpyrimidin-5-amine;

5-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)pyrimidine-2-carbonitrile;

6-(1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-1H-pyrrolo[2,3-c]pyridin-4- yl)pyridazine-3-carbonitrile;

1-((3,5-difluoro-4-(4-isopropylpiperazin-1-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-1Hpyrrolo[2,3-c]pyridine;

1-((4-(4-cyclopropylpiperazin-1-yl)-3,5-difluorophenyl)sulfonyl)-4-(pyridin-2-yl)-1Hpyrrolo[2,3-c]pyridine;

1-((3,5-difluoro-4-(4-methyl-1,4-diazepan-1-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-1Hpyrrolo[2,3-c]pyridine;

1-((4-(1,4-diazepan-1-yl)-3,5-difluorophenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3- c]pyridine;

1-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)piperidin4-amine;

1-((3,5-difluoro-4-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)phenyl)sulfonyl)-4-(pyridin-2- yl)-1H-pyrrolo[2,3-c]pyridine;

1-((3,5-difluoro-4-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)phenyl)sulfonyl)-4- (pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridine;

6-(2,6-difluoro-4-((4-(pyridin-2-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)sulfonyl)phenyl)-3-methyl3,6-diazabicyclo[3.1.1]heptane;

1-((3,5-difluoro-4-(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)phenyl)sulfonyl)-4-(pyridin2-yl)-1H-pyrrolo[2,3-c]pyridine;

1-((4-(1,4-diazabicyclo[3.2.1]octan-4-yl)-3,5-difluorophenyl)sulfonyl)-4-(pyridin-2-yl)-1Hpyrrolo[2,3-c]pyridine;

1-((3,5-difluoro-4-(2,6-diazaspiro[3.3]heptan-2-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-1Hpyrrolo[2,3-c]pyridine;

5-(1-((3,5-difluoro-4-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenyl)sulfonyl)- 1H-pyrrolo[2,3-c]pyridin-4-yl)-N-methylpyrazin-2-amine;

5-(1-((3,5-difluoro-4-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenyl)sulfonyl)- 1H-pyrrolo[2,3-c]pyridin-4-yl)pyrazine-2-carbonitrile;

5-(1-((3,5-difluoro-4-(5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenyl)sulfonyl)- 1H-pyrrolo[2,3-c]pyridin-4-yl)picolinonitrile;

1-((4-(2,5-diazabicyclo[2.2.1]heptan-2-yl)-3,5-difluorophenyl)sulfonyl)-4-(pyridin-2-yl)-1Hpyrrolo[2,3-c]pyridine (HCI salt);

1-((4-(3,8-diazabicyclo[3.2.1]octan-8-yl)-3,5-difluorophenyl)sulfonyl)-4-(pyridin-2-yl)-1Hpyrrolo[2,3-c]pyridine;

1-((3,5-difluoro-4-(piperazin-1-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3- c]pyridine (HCI salt);

5-(1-((3,5-difluoro-4-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenyl)sulfonyl)-1Hpyrrolo[2,3-c]pyridin-4-yl)picolinonitrile;

1-((3,5-difluoro-4-(4-methylpiperazin-1-yl)phenyl)sulfonyl)-4-(pyridin-2-yl)-1H-pyrrolo[2,3- c]pyridine (HCI salt).

18. A pharmaceutical composition for the treatment and/or prevention of a disease or condition that is mediated or maintained by CYP11B2 activity, comprising a therapeutically or prophylactically effective amount of a compound according to any one of claims 1 to 17 and at least one pharmaceutically acceptable excipient.

19. The pharmaceutical composition according to claim 18, characterized in that the pharmaceutically acceptable excipient is a carrier, adjuvant and/or solvent.

20. The pharmaceutical composition according to claim 18, characterized in that the disease is selected from the group including primary hyperaldosteronism, chronic heart failure, chronic heart failure with preserved ejection fraction, left ventricular dysfunction, left ventricular hypertrophy, arterial hypertension, resistant arterial hypertension, pulmonary arterial hypertension, coronary heart disease, liver cirrhosis, metabolic syndrome, chronic kidney disease, glomerulosclerosis, glomerulonephritis, nephritic syndrome, focal segmental glomerulosclerosis,

diabetic nephropathy, cardiac and vascular remodeling, postinfarction cardiosclerosis, atherosclerosis, increased collagen formation, endothelial dysfunction, hypokalemia, or insulin resistance.

21. The pharmaceutical composition according to claim 20, characterized in that primary hyperaldosteronism is Conn's syndrome, including the following diseases or conditions: aldosterone-producing adenoma, idiopathic hyperaldosteronism, unilateral or bilateral adrenal hyperplasia, familial hyperaldosteronism of the first and second type, aldosterone-producing carcinoma and aldosterone ectopic.